Artificial intelligence news.
Straight from the original announcements.

Beat AML reaches 10 years of precision medicine research in leukemia

November 17, 2026, 16:15By the AI News Bites Editorial TeamSource: PR Newswire

Blood Cancer United is marking 10 years of its Beat AML Master Clinical Trial, a precision medicine program that has provided genomic analysis to more than 2,000 patients with acute myeloid leukemia. The nonprofit says the trial has helped move treatment approaches from early research into phase 3 studies.

Key points
  • Beat AML has provided genomic analysis to more than 2,000 patients.
  • More than 720 patients enrolled across 17 clinical sub-studies.
  • The program has contributed to 65 publications and abstracts.
  • Beat AML now includes phase 1b, phase 2 and phase 3 research.
  • Investigators will present six Beat AML presentations at ASH 2026.

A master trial built around AML biology

Blood Cancer United launched Beat AML in 2016 to challenge the one-size-fits-all approach to treating acute myeloid leukemia, or AML. The trial uses genomic technology to identify genetic changes driving each patient’s disease and match eligible participants with treatment sub-studies based on that biology.

More than 2,000 patients have participated in the master protocol. Genomic analysis was provided with Foundation Medicine, and the trial originally aimed to complete comprehensive genomic and cytogenomic analysis and assign treatment within seven days.

According to Blood Cancer United, findings published in Nature Medicine in 2020 showed that Beat AML achieved that primary endpoint for 94.7% of eligible patients. More than 720 patients have enrolled across 17 clinical sub-studies, while Beat AML findings have contributed to 65 publications and abstracts.

Research now spans early studies through phase 3

Beat AML was initially designed for adults age 60 and older with newly diagnosed AML. Its scope has since expanded to patients age 18 and older, people with myelodysplastic syndrome, and patients with relapsed or refractory AML or MDS.

The program now covers phase 1b, phase 2 and phase 3 research. Its active studies include a phase 1b and phase 2 study of ficlatuzumab with azacitidine and venetoclax, as well as phase 3 studies of bleximenib or revumenib in defined patient groups.

One phase 1b study, BAML-16-001-S17, evaluated revumenib with azacitidine and venetoclax in adults with newly diagnosed AML involving NPM1 mutations or KMT2A rearrangements who were not eligible for intensive chemotherapy. Enrollment is complete, and the findings supported continued evaluation of the combination in phase 3 research through BAML-16-001-S26/HO177.

Blood Cancer United also highlighted results from the OPTI-AML sub-study. The research examined whether some older patients could receive a shorter course of venetoclax with azacitidine. The study found that the optimal duration varies by AML genetic mutation, according to the organization.

Why the milestone matters for AML care

AML is one of the most aggressive blood cancers and includes biologically distinct subtypes and rare genetic mutations that may respond differently to treatment. Blood Cancer United estimates that 22,700 people in the United States will be diagnosed with AML in 2026. Approximately 1 in 3 people living with AML survive five years after diagnosis, and many older patients cannot tolerate intensive chemotherapy.

Beat AML’s model combines genomic screening, multiple treatment sub-studies and shared infrastructure connecting academic investigators, treatment centers, genomic experts, companies, data specialists and clinical research organizations. In 2022, Blood Cancer United launched PedAL, extending the precision medicine master trial approach to pediatric acute leukemia.

“As Beat AML enters its second decade, we have an opportunity to build on that foundation by answering important treatment questions, evaluating new approaches and bringing clinical trials closer to patients,” said Alice Mims, M.D., Beat AML chief medical officer and a hematologist at The Ohio State University Comprehensive Cancer Center.

Beat AML investigators are scheduled to present three oral abstracts and three posters at the 2026 American Society of Hematology Annual Meeting and Exposition, taking place from Dec. 12-15, 2026, in New Orleans. The presentations include updated results from the revumenib combination study and findings from OPTI-AML.

Blood Cancer UnitedBeat AMLFoundation MedicineNature Medicinehealthcareresearch findings

Related news

AI review finds major gaps in how medical studies share code
ResearchNovember 19, 2026, 23:15

AI review finds major gaps in how medical studies share code

An MIT and Dana-Farber Cancer Institute-led team used large language models to examine nearly 4,000 clinical prediction studies and hundreds of code repositories. The…

Research
ResearchNovember 19, 2026, 15:00

Aidoc reports faster PE response and broader therapy use with AI workflows

AI-enabled pulmonary embolism workflows were linked to faster PERT activation, higher advanced therapy utilization and shorter hospital stays in research presented at…

MIT study links data center power use to air pollution far from facilities
ResearchNovember 19, 2026, 15:00

MIT study links data center power use to air pollution far from facilities

Electricity use by US data centers can worsen air quality and contribute to premature deaths in communities far from the facilities, according to a new MIT study.…